Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently proposed as an alternative disease concept to nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the prognosis of patients with biopsy-confirmed MASLD using data from a multicenter study. Methods: This was a sub-analysis of the Clinical Outcome Nonalcoholic Fatty Liver Disease (CLIONE) study that included 1,398 patients with NAFLD. Liver biopsy specimens were pathologically diagnosed and histologically scored using the NASH Clinical Research Network system, the FLIP algorithm, and the SAF score. Patients who met at least one cardiometabolic criterion were diagnosed with MASLD. Results: Approximately 99% of cases (n=1,381) were classified as MASLD. Patients with no cardiometabolic risk (n=17) had a significantly lower BMI than patients with MASLD (20.9 kg/m2 vs. 28.0 kg/m2, P<0.001), in addition to significantly lower levels of inflammation, ballooning, NAFLD activity score, and fibrosis stage based on liver histology. These 17 patients had a median follow-up of 5.9 years, equivalent to 115 person-years, with no deaths, liver-related events, cardiovascular events, or extrahepatic cancers. The results showed that the prognosis for pure MASLD was similar to that for the original CLIONE cohort, with 47 deaths and one patient who underwent orthotopic liver transplantation. The leading cause of death was extrahepatic cancer (n=10), while the leading causes of liver-related death were liver failure (n=9), hepatocellular carcinoma (n=8), and cholangiocarcinoma (n=4). Conclusions: Approximately 99% of NAFLD cases were considered MASLD based on the 2023 liver disease nomenclature. The NAFLD-only group, which is not encompassed by MASLD, had a relatively mild histopathologic severity and a favorable prognosis. Consequently, the prognosis of MASLD is similar to that previously reported for NAFLD.
Abstract
Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently proposed as an alternative disease concept to nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the prognosis of patients with biopsy-confirmed MASLD using data from a multicenter study. Methods: This was a sub-analysis of the Clinical Outcome Nonalcoholic Fatty Liver Disease (CLIONE) study that included 1,398 patients with NAFLD. Liver biopsy specimens were pathologically diagnosed and histologically scored using the NASH Clinical Research Network system, the FLIP algorithm, and the SAF score. Patients who met at least one cardiometabolic criterion were diagnosed with MASLD. Results: Approximately 99% of cases (n=1,381) were classified as MASLD. Patients with no cardiometabolic risk (n=17) had a significantly lower BMI than patients with MASLD (20.9 kg/m2 vs. 28.0 kg/m2, P<0.001), in addition to significantly lower levels of inflammation, ballooning, NAFLD activity score, and fibrosis stage based on liver histology. These 17 patients had a median follow-up of 5.9 years, equivalent to 115 person-years, with no deaths, liver-related events, cardiovascular events, or extrahepatic cancers. The results showed that the prognosis for pure MASLD was similar to that for the original CLIONE cohort, with 47 deaths and one patient who underwent orthotopic liver transplantation. The leading cause of death was extrahepatic cancer (n=10), while the leading causes of liver-related death were liver failure (n=9), hepatocellular carcinoma (n=8), and cholangiocarcinoma (n=4). Conclusions: Approximately 99% of NAFLD cases were considered MASLD based on the 2023 liver disease nomenclature. The NAFLD-only group, which is not encompassed by MASLD, had a relatively mild histopathologic severity and a favorable prognosis. Consequently, the prognosis of MASLD is similar to that previously reported for NAFLD.
참고문헌 (29)
- Rinella ME, "A multi-society Delphi consensus statement on new fatty liver disease nomenclature", Ann Hepatol, 29, pp.101133~ (2024)
- Kim GA, "Critical appraisal of metabolic dysfunction-associated steatotic liver disease : Implication of Janusfaced modernity", Clin Mol Hepatol, 29, pp.831~843 (2023)
- Yoon EL, "Waiting for the changes after the adoption of steatotic liver disease", Clin Mol Hepatol, 29, pp.844~850 (2023)
- "New NAFLD nomenclature"[URL]
- Song SJ, "Can we use old NAFLD data under the new MASLD definition?", J Hepatol, 80, pp.e54~e56 (2024)
- Hagström H, "99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical", J Hepatol, 80, pp.e76~e77 (2024)
- Fujii H, "Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients : A multicenter registry-based cohort study", Clin Gastroenterol Hepatol, 21, pp.370~379 (2023)
- Harris PA, "Research electronic data capture(REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support", J Biomed Inform, 42, pp.377~381 (2009)
- Harris PA, "The REDCap consortium : Building an international community of software platform partners", J Biomed Inform, 95, pp.103208~ (2019)
- American Diabetes Association, "Diagnosis and classification of diabetes mellitus", Diabetes Care, 33(Suppl 1), pp.S62~S69 (2010)
- Umemura S, "The Japanese society of hypertension guidelines for the management of hypertension(JSH 2019)", Hypertens Res, 42, pp.1235~1481 (2019)
- Teramoto T, "Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society(JAS)guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese", J Atheroscler Thromb, 14, pp.155~158 (2007)
- Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
- Brunt EM, "Nonalcoholic steatohepatitis : a proposal for grading and staging the histological lesions", Am J Gastroenterol, 94, pp.2467~2474 (1999)
- Bedossa P, "Utility and appropriateness of the fatty liver inhibition of progression(FLIP)algorithm and steatosis, activity, and fibrosis(SAF)score in the evaluation of biopsies of nonalcoholic fatty liver disease", Hepatology, 60, pp.565~575 (2014)
- Powell EE, "Non-alcoholic fatty liver disease", Lancet, 397, pp.2212~2224 (2021)
- Eslam M, "A new definition for metabolic dysfunctionassociated fatty liver disease : An international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
- Tsutsumi T, "MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD : Generalized estimating equation approach", Hepatol Res, 51, pp.1115~1128 (2021)
- Yamamura S, "MAFLD identifies patients with significant hepatic fibrosis better than NAFLD", Liver Int, 40, pp.3018~3030 (2020)
- Nguyen VH, "Differential clinical characteristics and mortality outcomes in persons with NAFLD and", or MAFLD, 2021, pp.19, 2172~2181
- Adams LA, "The natural history of nonalcoholic fatty liver disease : a population-based cohort study", Gastroenterology, 129, pp.113~121 (2005)
- Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397 (2015)
- Hagström H, "Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD", J Hepatol, 67, pp.1265~1273 (2017)
- Leung JC, "Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients", Hepatology, 65, pp.54~64 (2017)
- Ohira T, "Epidemiology of cardiovascular disease in Japan : An overview study", J Cardiol, 83, pp.191~200 (2024)
- Moon JH, "Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease : a nationwide cohort study", EClinicalMedicine, 65, pp.102292~ (2023)
- Carlsson B, "Review article : the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis", Aliment Pharmacol Ther, 51, pp.1305~1320 (2020)
- Nishioji K, "The impact of PNPLA3 rs738409 genetic polymorphism and weight gain ≥10 kg after Age 20 on nonalcoholic fatty liver disease in non-obese Japanese individuals", PLoS One, 10, pp.e0140427~ (2015)
- Seko Y, "The greater impact of PNPLA3 polymorphism on liverrelated events in Japanese non-alcoholic fatty liver disease patients : A multicentre cohort study", Liver Int, 43, pp.2210~2219 (2023)